Improved Quality of Life upon Shifting from Darbepoetin to Luspatercept in Patients with Low-Risk Myelodysplastic Syndrome (MDS)

被引：0
|
作者：
Almomen, Abdulkareem Mohammed [1 ,2 ]
Dwaima, Mohammed Eid [2 ]
Akkad, Hadeel Bashir [2 ]
Owaidah, Tarek M. [2 ]
机构：
[1] King Saud Univ, King Khalid Univ Hosp, Med, Riyadh, Saudi Arabia
[2] Natl Blood & Canc Ctr, Riyadh, Saudi Arabia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-178190
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [21] Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS
    Raghavan, Manoj
    Jenkins, Stephen
    Wintrich, Sophie
    Drayson, Mark
    Bunce, Chris
    Culligan, Dominic
    Kulasekararaj, Austin
    Wiseman, Dan
    Foster, Bethany
    Dunn, Janet
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 153 - 153
  • [22] Phase 2 randomised trial, repurposing Danazol and VBaP in low-risk myelodysplastic syndrome: REPAIR MDS
    Raghavan, Manoj
    Jenkins, Stephen
    Wintrich, Sophie
    Drayson, Mark
    Bunce, Chris
    Culligan, Dominic
    Kulasekararaj, Austin
    Wiseman, Dan
    Foster, Bethany
    Dunn, Janet
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 153 - 153
  • [23] Delayed response to lenalidomide in International Prognostic Scoring System (IPSS) low-risk myelodysplastic syndrome (MDS)
    Garcia, A. Mejia
    Asija, A.
    Besa, E. C.
    Giagounidis, A.
    Fonseca, G. A.
    LEUKEMIA RESEARCH, 2013, 37 : S111 - S111
  • [24] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Muzeyyen Aslaner Ak
    Birsen Sahip
    Ayfer Geduk
    Mehmer Ali Ucar
    Hacer Kale
    Tugba Hacibekiroglu
    Merve Gokcen Polat
    Yasin Kalpakci
    Ali Zahit Bolaman
    Birol Guvenc
    Sehmus Ertop
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 299 - 308
  • [25] The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study
    Ak, Muzeyyen Aslaner
    Sahip, Birsen
    Geduk, Ayfer
    Ucar, Mehmer Ali
    Kale, Hacer
    Hacibekiroglu, Tugba
    Polat, Merve Gokcen
    Kalpakci, Yasin
    Bolaman, Ali Zahit
    Guvenc, Birol
    Ertop, Sehmus
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (02) : 299 - 308
  • [26] Utilization Patterns and Outcomes from Iron Chelation in Elderly Patients with Low-Risk Myelodysplastic Syndrome
    Herrera, Diego Adrianzen
    Sparks, Andrew
    Singh, Rohit
    Giorgio, Katherine
    Lutsey, Pamela
    Zakai, Neil
    BLOOD, 2023, 142
  • [27] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Eric J. Feldman
    Current Hematologic Malignancy Reports, 2011, 6 : 1 - 2
  • [28] Should Patients with Low-Risk Myelodysplastic Syndrome be Treated Earlier in the Course of Their Disease?
    Feldman, Eric J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2011, 6 (01) : 1 - 2
  • [29] INFERIOR OUTCOME IN LOW-RISK MYELODYSPLASTIC SYNDROME PATIENTS EXHIBITING IRON OVERLOAD
    Sumoza, M.
    Yellapragada, S.
    Roque, W.
    Mims, M.
    Rivero, G.
    LEUKEMIA RESEARCH, 2015, 39 : S138 - S138
  • [30] THE COST OF BLOOD TRANSFUSION IN LOW-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): AN ECONOMIC ANALYSIS FOR THE CASE OF GREECE
    Fragoulakis, B.
    Maniadakis, N.
    Panagiotidis, P.
    HAEMATOLOGICA, 2012, 97 : 145 - 146
12345